Occurrence of Fosamax jaw bone decay is likely to increase
Although Fosamax was approved by the FDA in 1995, the first reports of jaw bone decay side effects did not surface until early 2005. The reason for this long delay is that the risk of jaw bone deterioration increases with long term use of the medication.
Fosamax has an extremely long half life of over 10 years. Since the medication remains in the system for so long and users are encouraged to continue taking Fosomax to reduce the risk of fractures, dose accumulation will occur over time.
Saiontz, Kirk & Miles has been investigating claims for Fosamax side effects since early 2006. In the coming years, it is expected that the number of individuals who suffer from osteonecrosis of the jaw as a result of Fosamax will increase dramatically for the following reasons:
- Fosamax is a very popular medication which has been taken by over 20 million Americans.
- Merck, the manufacturer, promotes it as something older women will need to take for the rest of their lives (”Fosamax for life”).
- Merck continues to not adequately?warn of the dangers of Fosamax.
For more information on these claims, visit the Fosamax section of our website. If you have suffered an injury as a result of taking Fosamax, or wish to speak with an attorney regarding this claim, request a free consultation.
